Argenx's Vygart launch finds quick neurologist support over AstraZeneca's well-entrenched Soliris for myasthenia gravis

Argenx nabbed an FDA approval for its rare disease drug Vyvgart just before Christmas and is wasting no time launching the generalized myasthenia gravis (gMG) med and setting it up to compete with AstraZeneca's Soliris.